NEW YORK (GenomeWeb News) – The New York Genome Center's Founding Executive Director Nancy Kelley is leaving her post, NYGC said this week, although she will continue to serve as an advisor and remain on the center's board of directors.
Kelley was a leader of the effort, along with 11 institutional founding members, to establish NYGC and to settle it into its current location in downtown Manhattan.
Pacific Biosciences said in a filing with the US Securities and Exchange Commission that Susan Siegel has resigned from her seat on the firm's board of directors and that David Singer will not stand for re-election at the company's 2013 stockholder's meeting.
Real Time Genomics has formed its scientific advisory board, which includes founding members George Weinstock, Timothy Triche, and Gene Myers.
Weinstock is associate director of The Genome Institute at Washington University School of Medicine, and he was a leader of the Human Microbiome Project and co-director of the Human Genome Sequencing Center at the Baylor College of Medicine.
Triche is director of the Center for Personalized Medicine at Children's Hospital Los Angeles and the associate director of the Pediatric Institute of Molecular Medicine at Phoenix Children's Hospital.
Myers is director of the Center for Systems Biology at the Max Planck Institute, Dresden, and he is the creator of BLAST, the whole-genome shotgun protocol and assembler bioinformatics technology, which he applied while he was VP of informatics research at Celera Genomics.
TrovaGene said this week that it has appointed Mark Elander as chief scientific officer. Elander will direct the clinical development program for the company's portfolio of transrenal and urine-based molecular diagnostic assays. He will also oversee the ongoing clinical program for Trovagene's human papilloma virus carrier screening assay.
Elander previously served as CSO of BioTheranostics, a BioMérieux company. Prior to this, he was a research fellow at the RW Johnson Pharmaceutical Research Institute, part of Johnson & Johnson. He has also been a postdoctoral fellow in the Department of Molecular Biology at Scripps Research Institute.
Molecular diagnostics developer Rheonix has named Steven Pemberton to be VP of marketing and sales and Bryan Greene to be director of consumable manufacturing.
Pemberton formerly held leadership posts at Abbott Diagnostics, Ventana Medical Systems, and Roche Diagnostics. Greene previously was responsible for design transfer and products manufacturing at Life Technologies.
Bruker has named Anthony Mattacchione to serve as senior VP of corporate finance and accounting.
Mattacchione previously was chief financial officer of EMD Millipore and VP, controller, and chief accounting officer of Millipore. He also held a range of financial roles at Gerber Scientific over a 16-year period.
He will receive a base salary of $280,000, an annual bonus based on a 2013 target level of $140,000, and a grant of options to purchase 40,000 shares of the company's common stock.
Combimatrix said recently that its board of directors has elected Mark McDonough, who is soon to take over as president and CEO, and current company Chief Medical Officer Richard Hockett to serve on its board of directors, effective immediately.
McDonough, who came to CombiMatrix last August from Pathwork Diagnostics, is slated to assume the CEO post on March 15.
Caris Life Sciences has named Joachim Schorr to be its chief scientific officer.
Schorr formerly worked for two decades at Qiagen, where he was senior VP of global R&D, managing director, and a member of the executive committee, and held other posts. He will continue to serve as a scientific consultant for Qiagen.
Sigma-Aldrich has appointed Archie Cullen to be president of BioReliance, a biologics testing firm Sigma-Aldrich acquired last year. He is replacing Charles Harwood, who is retiring. Cullen was previously vice president of Sigma-Aldrich's custom manufacturing and services business unit, SAFC, and has also held positions at Life Technologies and JRH Biosciences.
Integrated Diagnostics has appointed John Bencich to be CFO and Jill Tonachio to be VP of sales. They both will work on the planned launch of the firm's lung cancer blood diagnostic test later this year.
Bencich previously was CFO at Allozyne and president, CFO, and treasurer at Trubion Pharmaceuticals. Tonachio recently was national director of sales for Aurora Diagnostics, she was director of strategic accounts at Aureon Laboratories, and she has held posts at Labcorp, Dianon Systems, and Johnson and Johnson.
Curetis this week said that it has appointed Helmut Hilbert as head of business development.
Hilbert was previously employed at Qiagen, where he served in a number of scientific and business development positions, most recently associate director of corporate business development.
Accelerate Diagnostics said this week that it has tapped Frank ten Brink to join its board of directors. Ten Brink currently is executive VP, CFO and chief administrative officer of Stericycle, and he formerly was CFO at Telular, and VP and CFO at Hexacomb.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.